1-5 of 5
David Schenkein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

Free
Eytan Stein, Martin Tallman, Daniel A. Pollyea, Ian W. Flinn, Amir T. Fathi, Richard M. Stone, Ross L. Levine, Samuel Agresta, David Schenkein, Hua Yang, Bin Fan, Kate Yen, Stephane D. Botton
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT103.
https://doi.org/10.1158/1538-7445.AM2014-CT103
Published: 01 October 2014
View articletitled, Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
Journal Articles

Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model

Free
Kate Ellwood-Yen, Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, Sam Agresta, David Schenkein, Scott Biller, Michael Su
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3116.
https://doi.org/10.1158/1538-7445.AM2014-3116
Published: 01 October 2014
View articletitled, Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
Journal Articles

Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model

Free
Kate Ellwood-Yen, Yue Chen, Fang Wang, Rene Lemieux, Janeta Popovici-Muller, Hua Yang, Kimberly Straley, Sung Choe, Marion Dorsch, Sam Agresta, David Schenkein, Scott Biller, Michael Su
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1194.
https://doi.org/10.1158/1538-7445.AM2014-1194
Published: 01 October 2014
View articletitled, Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model
Journal Articles

Abstract LB-164: IDH mutations and tumorgenicity

Free
Kate Yen, Fang Wang, Sung Choe, Stefanie Schalm, Erica Hansen, Kimberly Straley, Janeta Popovici-Muller, Jeremy Travins, Hua Yang, Lee Silverman, William Kaelin, Stefan Gross, Lenny Dang, Frank Salituro, Jeff Saunders, David Schenkein, Michael Su, Scott Biller
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): LB-164.
https://doi.org/10.1158/1538-7445.AM2012-LB-164
Published: 15 April 2012
View articletitled, Abstract LB-164: IDH mutations and tumorgenicity
Journal Articles

The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines

Free
Sandra J. Strauss, Karen Higginbottom, Simone Jüliger, Lenushka Maharaj, Paul Allen, David Schenkein, T. Andrew Lister, Simon P. Joel
Journal: Cancer Research
Cancer Res (2007) 67 (6): 2783–2790.
https://doi.org/10.1158/0008-5472.CAN-06-3254
Published: 15 March 2007
View articletitled, The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines
Open the PDF for The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines in another window